In a perfect world patients enrolled in clinical trials would live a short distance from the investigator site where they receive their treatment.
Unfortunately that is not always the case. In recent years the Direct-to-Patient model, which brings medical procedures to a patient’s home, has emerged as a solution for Sponsors to increase patient recruitment and retention in clinical trials.
A pharmaceutical manufacturer was working with Thermo Fisher Scientific in support of multiple clinical trials and protocols. Patients enrolled in these trials were occasionally unable to maintain an appointment at their respective investigator site. The circumstances were many and varied.
The Sponsor recognized that providing Direct-to-Patient service on an exception basis would meet a critical need. Because the patients participating in these trials were able to self-medicate, it was strictly the residential delivery that needed to be addressed.
Read how the close collaboration of sponsor, Clinical Investigator Site, Thermo Fisher Scientific and the specialty logistics team was able remove a costly and time-consuming transportation burden for the patient, and provide an uninterrupted flow of medication that is critical to their treatment.